Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamoxifen oral liquid - Rosemont Pharmaceuticals

Drug Profile

Tamoxifen oral liquid - Rosemont Pharmaceuticals

Alternative Names: Soltamox; Tamoxifen citrate; Tamoxifen oral liquid solution - Rosemont Pharmaceuticals

Latest Information Update: 17 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rosemont Pharmaceuticals Ltd; University of Birmingham
  • Developer Rosemont Pharmaceuticals Ltd
  • Class Antineoplastics; Chemopreventatives; Dimethylamines; Infertility therapies; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 13 Nov 2018 Midatech Pharma US has been acquired by Kanwa Holdings
  • 06 Jan 2015 DARA Biosciences receives product and establishment fee waiver from the FDA
  • 29 Oct 2014 DARA BioSciences files a petition with US FDA for a label update for Tamoxifen oral liquid as an adjuvant therapy for breast cancer, from five to ten years .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top